Second- and third-generation ALK inhibitors for non-small cell lung cancer

被引：0

作者：

Jingjing Wu

John Savooji

Delong Liu

机构：

[1] The First Affiliated Hospital of Zhengzhou University,Department of Oncology

[2] Westchester Medical Center and New York Medical College,Department of Medicine

来源：

Journal of Hematology & Oncology | / 9卷

关键词：

Brain Metastasis; Pemetrexed; Anaplastic Lymphoma Kinase; Anaplastic Large Cell Lymphoma; Crizotinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.

引用

共 50 条

[1] Second- and third-generation ALK inhibitors for non-small cell lung cancer
Wu, Jingjing
Savooji, John
Liu, Delong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[2] A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors
Mitsuya, S.
Tsuruoka, K.
Kanaoka, K.
Funamoto, T.
Tsuji, H.
Matsunaga, N.
Nakamura, T.
Tamura, Y.
Imanishi, M.
Ikeda, S.
Fujisaka, Y.
Goto, I.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S596 - S596
[3] Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer
Bauman, Jessica R.
Liu, Geoffrey
Preeshagul, Isabel
Liu, Stephen V.
Melosky, Barbara
Abrahami, Devin
Li, Benjamin
Thomaidou, Despina
Duncan, Kirsten
Krulewicz, Stan
Rupp, Martin
Lin, Jessica J.
LUNG CANCER, 2024, 195
[4] Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]
Bauman, Jessica R.
Liu, Geoffrey
Preeshagul, Isabel
V. Liu, Stephen
Melosky, Barbara
Abrahami, Devin
Li, Benjamin
Thomaidou, Despina
Duncan, Kirsten
Krulewicz, Stan
Rupp, Martin
Lin, Jessica J.
LUNG CANCER, 2024, 197
[5] Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).
Tatineni, Vineeth
O'Shea, Patrick Joseph
Rauf, Yasmeen
Jia, Xuefei
Murphy, Erin Sennett
Chao, Samuel T.
Suh, John H.
Peereboom, David M.
Ahluwalia, Manmeet Singh
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Second generation ALK inhibitors in non-small cell lung cancer: Systemic review
Viala, Marie
Brosseau, Solenn
Planchard, David
Besse, Benjamin
Soria, Jean-Charles
BULLETIN DU CANCER, 2015, 102 (04) : 381 - 389
[7] Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors
Spagnuolo, Alessia
Maione, Paolo
Gridelli, Cesare
EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (03) : 231 - 241
[8] Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer (vol 195, 107919, 2024)
Bauman, Jessica R.
Liu, Geoffrey
Preeshagul, Isabel
V. Liu, Stephen
Melosky, Barbara
Abrahami, Devin
Li, Benjamin
Thomaidou, Despina
Duncan, Kirsten
Krulewicz, Stan
Rupp, Martin
Lin, Jessica J.
LUNG CANCER, 2025, 201
[9] Second- and third-line treatments in non-small cell lung cancer
Kumar A.
Wakelee H.
Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
[10] The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance
Haratake, Naoki
Toyokawa, Gouji
Seto, Takashi
Tagawa, Tetsuzo
Okamoto, Tasuro
Yamazaki, Koji
Takeo, Sadanori
Mori, Masaki
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 975 - 988

← 1 2 3 4 5 →